NVS novartis.com Price-to-Projected Revenue Ratio

Brandmark of Novartis Inc. (NVS)

Stable prescription drug sales guarantee Novartis AG (NVS) a reliable capital inflow, which is confirmed by the current forward P/S ratio. The value 3.00 reflects the current magnitude of this metric. Amid the struggle against generics and R&D expenditures, the company is optimizing its workforce while retaining key scientists to develop new molecules and maintain business competitiveness.

NVS Novartis Corporation: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Novartis Pharma (NVS)

- current price and projected stock value:
Stock Price Novartis|NVS - Analyst Target Range
- market capitalization data:
Market Value Novartis Pharma|NVS - Business Value
- book value of equity indicators:
Net Assets per Single Share Novartis|NVS - Total Stockholders' Equity|Market Cap to Net Assets Ratio novartis.com|NVS - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Novartis AG|NVS - Long-Term Debt to Capital|Short-Term Debt to Equity Novartis AG|NVS - Aggregate Debt Obligations|Debt to Book Value Novartis Pharma|NVS - Amount of Long-Term Liabilities|Company Short-Term Debts Novartis|Quick Liquidity novartis.com
- business earnings and investment ratios data:
NVS - Net Financial Result|Future Profit Novartis AG|NVS - Company Value to Net Income|Forward P/E Multiple Novartis Inc.|NVS - PEG Multiple|EV/EBITDA Multiple Novartis Pharma|NVS - Operating profit before depreciation charges|Earnings per share for the last twelve months Novartis|NVS - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months novartis.com|NVS - Earnings per share growth in current year|Net earnings per share growth forecast for next year Novartis AG
- revenue and sales details:
NVS - Company Gross Revenue|Company Projected Revenue Novartis|NVS - Price-to-Sales Ratio|Forward P/S Multiple Novartis Pharma
Summary company analysis:Novartis (NVS)
Product sample of Novartis AG

The transformation of Novartis AG (NVS) into a specialized developer of high-margin biologics and gene therapies is altering its revenue structure. By analyzing the forward P/S trend, an investor compares the company's current market value with projected sales volumes. This ratio determines how much the market is willing to pay per unit of future revenue, confirming either the justification for a premium valuation of innovations or the overbought nature of the capital.

Competing companies

Forward P/S Multiple LLY (Eli Lilly)|Projected Price to Revenue AbbVie Inc|AZN - Price-to-Projected Revenue Ratio|MRK (MSD) - Market Cap to Projected Revenue|Novo Nordisk A/S (NVO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio amgen.com (AMGN)|Forward Price-to-Revenue Multiple PFE|Price-to-Projected Revenue Ratio SNY|Forward P/S Multiple BMY|Forward P/S Multiple gsk.com (GSK)|Price-to-Projected Revenue Ratio Takeda Pharmaceutical TAK|Forward Price to Sales TEVA|RDY: Forward Price-to-Revenue Multiple|Viatris Inc - Price to Expected Revenue Ratio|ROIV: Forward P/S Multiple|ZLAB - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bausch Health Companies|cosmosholdingsinc.com (COSM) - Market Cap to Expected Sales Ratio